Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research Journal Social Sciences and Humanioran Review
Chyntia
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Neuroscience Social Sciences Other

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
THE ROLE OF DOMESTIC INVESTMENT (DI) AND BUSINESS, MICRO, SMALL AND MEDIUM (MSMEs) IN INVESTMENT IN INDONESIA Graceya Iranita Tarigan; widia; Alivia Putri Aina; Chyntia; Nathaniela Putri Arumdhani; Luna Diana Puteri
Journal Social Sciences and Humanioran Review Vol. 1 No. 04 (2024): JULY
Publisher : Zhata Institut

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

One indicator of a country's national development is its economic growth. Economic development is an indicator to find out how successful a country's economic development is and also as a determinant of development policies that will be formed next. Economic growth and development aim to increase job opportunities for the community, which must involve all levels of society in its implementation. One component that plays an important role in Indonesia's economic growth is Micro, Small and Medium Enterprises (UMKM) and also Domestic Investment (PMDN). UMKM plays a role in the absorption of labor so that they also contribute to national income. However, the economic growth of a country can also be helped by investment. This research is a normative legal research using secondary data, as well as a statutory approach which is then compiled qualitatively. The conclusion of this study shows that the role of UMKM in the development of investment in Indonesia is in terms of expanding the provision of employment, making a significant contribution to the development of a country, distributing income increases and increasing the competitiveness and resilience of the national economy. Meanwhile, PMDN plays a role in financing which is important for developing regions and is able to make a sizable contribution to development and plays a role in increasing economic growth through a conducive investment climate in Indonesia.
Clinical Characteristics and Progression of Osteogenesis Imperfecta Type III: A Case Series Edbert Wielim; Chyntia; Regina Suriadi; I Wayan Bikin Suryawan
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1268

Abstract

Background: Osteogenesis imperfecta (OI) is a rare genetic disorder primarily affecting bone formation, leading to increased bone fragility and fractures. OI Type III is characterized by severe clinical manifestations, including multiple fractures, skeletal deformities, and short stature. This case series describes the clinical characteristics and progression of three patients diagnosed with OI Type III, highlighting the impact of early intervention with zoledronic acid on their outcomes. Case presentation: This study presents three cases of OI Type III in female patients. Two patients (Patient A and Patient R) were diagnosed at birth with multiple fractures and received zoledronic acid treatment starting at three months of age. The third patient (Patient D) presented with fractures later in infancy and began treatment at one year of age. All patients demonstrated hallmark features of OI Type III, including blue sclerae, short stature, and progressive skeletal deformities. However, the two patients who received earlier treatment with zoledronic acid showed better mobility and fewer fractures compared to the patients who started treatment later. Conclusion: This case series emphasizes the importance of early diagnosis and intervention in OI Type III. Zoledronic acid appears to be effective in reducing fracture rates and improving mobility in these patients. Further studies with larger sample sizes are needed to confirm these findings and optimize treatment strategies for OI Type III.
Clinical Characteristics and Progression of Osteogenesis Imperfecta Type III: A Case Series Edbert Wielim; Chyntia; Regina Suriadi; I Wayan Bikin Suryawan
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1268

Abstract

Background: Osteogenesis imperfecta (OI) is a rare genetic disorder primarily affecting bone formation, leading to increased bone fragility and fractures. OI Type III is characterized by severe clinical manifestations, including multiple fractures, skeletal deformities, and short stature. This case series describes the clinical characteristics and progression of three patients diagnosed with OI Type III, highlighting the impact of early intervention with zoledronic acid on their outcomes. Case presentation: This study presents three cases of OI Type III in female patients. Two patients (Patient A and Patient R) were diagnosed at birth with multiple fractures and received zoledronic acid treatment starting at three months of age. The third patient (Patient D) presented with fractures later in infancy and began treatment at one year of age. All patients demonstrated hallmark features of OI Type III, including blue sclerae, short stature, and progressive skeletal deformities. However, the two patients who received earlier treatment with zoledronic acid showed better mobility and fewer fractures compared to the patients who started treatment later. Conclusion: This case series emphasizes the importance of early diagnosis and intervention in OI Type III. Zoledronic acid appears to be effective in reducing fracture rates and improving mobility in these patients. Further studies with larger sample sizes are needed to confirm these findings and optimize treatment strategies for OI Type III.
Co-Authors Alivia Putri Aina Edbert Wielim Graceya Iranita Tarigan I Wayan Bikin Suryawan Luna Diana Puteri Nathaniela Putri Arumdhani Regina Suriadi Widia